Apollomics reports first half 2024 financial results and highlights vebreltinib clinical progress

Foster city, calif., aug. 14, 2024 (globe newswire) -- apollomics inc. (nasdaq: aplm) (“apollomics” or the “company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2024 ended june 30, 2024, and highlighted updates for its pipeline.
APLM Ratings Summary
APLM Quant Ranking